JP2020529864A5 - - Google Patents

Info

Publication number
JP2020529864A5
JP2020529864A5 JP2020520427A JP2020520427A JP2020529864A5 JP 2020529864 A5 JP2020529864 A5 JP 2020529864A5 JP 2020520427 A JP2020520427 A JP 2020520427A JP 2020520427 A JP2020520427 A JP 2020520427A JP 2020529864 A5 JP2020529864 A5 JP 2020529864A5
Authority
JP
Japan
Prior art keywords
domain
triplicate
binding specificity
acid sequence
percentage homology
Prior art date
Application number
JP2020520427A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020529864A (ja
JP7356970B2 (ja
JPWO2019005637A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/039153 external-priority patent/WO2019005637A2/en
Publication of JP2020529864A publication Critical patent/JP2020529864A/ja
Publication of JP2020529864A5 publication Critical patent/JP2020529864A5/ja
Publication of JPWO2019005637A5 publication Critical patent/JPWO2019005637A5/ja
Application granted granted Critical
Publication of JP7356970B2 publication Critical patent/JP7356970B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020520427A 2017-06-25 2018-06-22 多重特異性抗体とその作製及び使用方法 Active JP7356970B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762524554P 2017-06-25 2017-06-25
US62/524,554 2017-06-25
PCT/US2018/039153 WO2019005637A2 (en) 2017-06-25 2018-06-22 MULTIPECIFIC ANTIBODIES AND METHODS OF PRODUCTION AND USE THEREOF

Publications (4)

Publication Number Publication Date
JP2020529864A JP2020529864A (ja) 2020-10-15
JP2020529864A5 true JP2020529864A5 (https=) 2022-02-07
JPWO2019005637A5 JPWO2019005637A5 (https=) 2022-02-07
JP7356970B2 JP7356970B2 (ja) 2023-10-05

Family

ID=64742648

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020520427A Active JP7356970B2 (ja) 2017-06-25 2018-06-22 多重特異性抗体とその作製及び使用方法

Country Status (5)

Country Link
US (2) US11649286B2 (https=)
EP (1) EP3645050A4 (https=)
JP (1) JP7356970B2 (https=)
CN (1) CN111148761B (https=)
WO (1) WO2019005637A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
TWI828625B (zh) * 2017-06-25 2024-01-11 美商西雅圖免疫公司 引導及導航控制蛋白質以及彼之製造及使用方法
CN110799538B (zh) * 2017-08-28 2023-08-01 西雅图免疫公司 抗cd3抗体及其制备和使用方法
AU2019228128A1 (en) * 2018-03-02 2020-09-03 Cdr-Life Ag Trispecific antigen binding proteins
CN116407626A (zh) * 2020-01-29 2023-07-11 美勒斯公司 用于调节免疫细胞衔接效应的手段和方法
TWI888487B (zh) * 2020-02-14 2025-07-01 日商協和麒麟股份有限公司 與ｃｄ３結合之雙特異性抗體
LT4269444T (lt) 2020-08-14 2024-09-25 GammaDelta Therapeutics Limited Daugiaspecifiniai anti-tcr kintamos delta 1 antikūnai
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
CA3192204A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
WO2022094299A2 (en) * 2020-10-30 2022-05-05 Janux Therapeutics, Inc. Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof
US20250074996A1 (en) * 2021-02-19 2025-03-06 Innovent Biologics (Suzhou) Co., Ltd. ANTI-GPRC5DxBCMAxCD3 TRISPECIFIC ANTIBODY AND USE THEREOF
CN114853897B (zh) * 2021-04-15 2024-01-26 北京大学深圳研究生院 抗cd19/cd22/cd3三特异性抗体及用途
CA3216342A1 (en) * 2021-04-23 2022-10-27 Hassan ISSAFRAS Anti-gpc3 antibodies, multispecific antibodies and methods of use
CN119110809A (zh) 2022-02-23 2024-12-10 Xencor股份有限公司 抗CD28 x抗PSMA抗体
CN115305237B (zh) * 2022-07-08 2023-07-14 中南大学 一种优化的调节性t细胞的扩增及规模化生产的方法
WO2024160721A1 (en) 2023-01-30 2024-08-08 Kymab Limited Antibodies
KR20250157389A (ko) * 2023-03-01 2025-11-04 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Fap/4-1bb/cd40 결합 분자 및 이의 의학적 용도
CN121398845A (zh) * 2023-07-14 2026-01-23 嘉和生物药业有限公司 抗pd-1/ctla-4/tigit三特异性抗体及其用途
WO2025059589A1 (en) * 2023-09-13 2025-03-20 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Immune cell engaging molecules
WO2026052000A1 (zh) * 2024-09-04 2026-03-12 上海迈晋生物医药科技有限公司 包含fap/4-1bb/cd40结合分子的药物组合物及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60333228D1 (de) * 2002-12-02 2010-08-12 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
WO2010028796A1 (en) * 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Trispecific hexavalent antibodies
JP6190723B2 (ja) * 2010-12-01 2017-08-30 アルダーバイオ ホールディングス エルエルシー 抗ｎｇｆ組成物およびその使用
GB201020995D0 (en) * 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
EP2789630A1 (en) * 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
WO2014191113A1 (en) * 2013-05-28 2014-12-04 Numab Ag Novel antibodies
CN105722859B (zh) * 2013-07-25 2021-05-07 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
JP7020909B2 (ja) * 2014-07-25 2022-02-16 シトムクス セラピューティクス，インコーポレイティド 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法
EP3204415B1 (en) * 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
WO2016105450A2 (en) * 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
EP3288975A1 (en) * 2015-04-29 2018-03-07 Institute for Research in Biomedicine Ultra-potent neutralization of cytokines by multispecific antibodies and uses thereof
DK3317301T3 (da) * 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
JP6932700B2 (ja) * 2015-09-15 2021-09-08 アムジエン・インコーポレーテツド ４価の二重特異性抗原結合タンパク質及び４価の四重特異性抗原結合タンパク質、ならびにそれらの使用

Similar Documents

Publication Publication Date Title
JP2020529864A5 (https=)
JP2020530777A5 (https=)
JP2020530306A5 (https=)
JP7685095B2 (ja) 多重特異性抗体とその作製及び使用方法
JPWO2019005637A5 (https=)
JP2021519072A5 (https=)
JP7399852B2 (ja) 多重特異性抗体とその作製及び使用方法
CA3108915A1 (en) Proteins binding nkg2d, cd16 and a tumor-associated antigen
JP2020501531A5 (https=)
JP2020531043A5 (https=)
CN117285641A (zh) 制导和导航控制蛋白及其制备和使用方法
Urbanska et al. Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells
JPWO2019191120A5 (https=)
JPWO2019005640A5 (https=)
JP2021501575A (ja) 二重特異性抗体並びにその製造方法及び使用方法
JPWO2019005639A5 (https=)
HK40111323A (zh) 多特异性抗体及其制备和使用方法
HK40111322A (zh) 多特异性抗体及其制备和使用方法
HK40088418A (zh) 多特异性抗体及其制备和使用方法
HK40093821A (zh) 多特异性抗体及其制备和使用方法
HK40088417A (zh) 多特异性抗体及其制备和使用方法
HK40097105A (zh) 双特异性抗体及其制备和使用方法
Li et al. Advancing immunotherapy via multiple immune cells co-engagement
HK40109798A (zh) 制导和导航控制蛋白及其制备和使用方法
HK40097671A (zh) 制导和导航控制蛋白及其制备和使用方法